Restructuring watch

Restructuring watch

Date Company Staff cuts Cash Years cash pre-cut Cash reporting date 1Q05 oper loss
3/31/05 XTL (LSE:XTL) 31% to 45 $23.0 1.4 12/31/04 $16.8 (A)
Halted all R&D except on HepeX-C for HCV and preclinical HCV-SM small molecule program. Plans to in-license or acquire additional clinical product candidates.
4/19/05 Corgentech (CGTK) 45% to 70 $101.4 1.8 3/31/05 $14.4
Restructuring follows CGTK's decision to discontinue development

Read the full 677 word article

How to gain access

Continue reading with a
two-week free trial.